This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Amdipharm Mercury Company Limited

No. 1 Croydon, 12 - 16 Addiscombe Road, Croydon, Surrey, CR0 0XT, UK
Telephone: +44 (0)208 588 9100
Fax: +44 (0)208 686 0807
Medical Information Direct Line: 08700 70 30 33
Medical Information e-mail:
Customer Care direct line: +44 (0)208 588 9273
Medical Information Fax: +44 (0)208 686 0807

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 15/05/2013
SPC Diconal Tablets / Dipipanone+Cyclizine 10 mg+30 mg Tablets

Go to top of the page
1. Name of the medicinal product

Diconal Tablets.

Dipipanone/Cyclizine 10 mg/30 mg Tablets.

Go to top of the page
2. Qualitative and quantitative composition

Each tablet contains 10 mg of Dipipanone Hydrochloride BP and 30 mg of Cyclizine Hydrochloride BP, coloured deep pink, scored and coded 'F3A'.

Go to top of the page
3. Pharmaceutical form


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Diconal Tablets are indicated for the management of moderate to severe pain in medical and surgical conditions in which morphine may be indicated.

Cyclizine is effective in preventing nausea and vomiting associated with the administration of narcotic analgesics.

Go to top of the page
4.2 Posology and method of administration

Adults: The initial dose in all conditions is one tablet every 6 hours. It is unwise to exceed this dose in view of the difficulty in accurately predicting the initial central effects of dipipanone.

Should this dose fail to prove adequate analgesia, as in severe intractable pain or when other potent opioids have been used, it may be increased by half a tablet every six hours.

It is seldom necessary to exceed a dose of 30 mg dipipanone given 6-hourly (i.e. 12 tablets in 24 hours).

Children: There is no specific information on the use of Diconal in children. Diconal is very rarely indicated in children and dosage guidelines cannot be stated.

Use in the elderly: There is no specific information on the use of Diconal in elderly patients. In common with opioid drugs, Diconal may be expected to cause confusion in this age group, and careful monitoring is advised (see Precautions).

Go to top of the page
4.3 Contraindications

Diconal is contraindicated in individuals who are hypersensitive to dipipanone or cyclizine.

Diconal is generally contraindicated in patients with respiratory depression, especially in the presence of cyanosis and excessive bronchial secretions.

Diconal should not be given during an attack of bronchial asthma.

Diconal is generally contraindicated in the presence of acute alcoholism, head injury and raised intracranial pressure.

Diconal is contraindicated in individuals receiving monoamine oxidase inhibitors, or within 14 days of stopping such treatment.

Diconal is contraindicated in patients with ulcerative colitis since in common with other narcotic analgesics it may precipitate toxic dilatation or spasm of the colon.

As with all narcotic analgesics Diconal should not be administered to patients with severe hepatic impairment as it may precipitate hepatic encephalopathy.

In severe renal impairment Diconal, in common with all narcotic analgesics, may precipitate coma and should not be administered.

Diconal, in common with morphine and most other narcotics, may cause spasm of the biliary and renal tracts; it is contraindicated in these conditions.

Go to top of the page
4.4 Special warnings and precautions for use

The repeated use of Diconal may lead to tolerance and physical dependence as well as to psychological dependence on the product.

Misuse of Diconal has been reported, particularly by young addicts who have previously been dependent on, or have misused other agents both opiate and non-opiate. Extreme caution is warranted when prescribing Diconal to this group of patients.

Diconal should be used with extreme caution in the presence of the following: hypothyroidism; adrenocortical insufficiency; prostatic hypertrophy; hypotension secondary to hypovolaemic shock; diabetes mellitus.

Diconal is metabolised in the liver and excreted along with its metabolites in the urine. Where not contraindicated in patients with impaired hepatic and/or renal function, Diconal should be given at less than the usual recommended dose, and the patient's response used as a guide to further dosage requirements.

Extreme caution should be exercised when administering Diconal to patients with phaeochromocytoma, since hypertension has been reported in association with other potent opioids.

No data are available as to whether or not dipipanone has carcinogenic, mutagenic or teratogenic potential. It is not known whether cyclizine has carcinogenic or mutagenic potential. Some animal studies are interpreted as indicating that cyclizine may be teratogenic, but relevance to the human situation is not known.

In a study involving prolonged administration of cyclizine to male and female rats, there was no evidence of impaired fertility after continuous treatment for 90-100 days. There are no similar data for dipipanone. There is no information on the effect of Diconal on human fertility.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The central nervous system depressant effects of Diconal may be increased by phenothiazine drugs, alcohol, sedatives and tricyclic antidepressants. Concurrent administration of some phenothiazines increases the respiratory depressant effects of narcotic analgesics and also produces hypotension.

Because of its anticholinergic activity, cyclizine may enhance the side effects of other anticholinergic agents.

Analgesic effects of opioid drugs tend to be enhanced by co-administration of dexamphetamine, however their use in combination is not recommended.

Go to top of the page
4.6. Pregnancy and lactation

The use of Diconal during pregnancy is not recommended. No data are available on the therapeutic use of Diconal in human pregnancy. It may be anticipated that if given in the last trimester, Diconal would cause withdrawal symptoms in the neonate.

Diconal is not recommended for use in labour because of its potential to cause respiratory depression in the neonate.

No data are available on the excretion of dipipanone, cyclizine or their metabolites in human milk.

Go to top of the page
4.7 Effects on ability to drive and use machines

Ambulatory patients receiving Diconal should be cautioned against driving cars or operating machinery in view of its tendency to cause drowsiness.

Go to top of the page
4.8 Undesirable effects

The adverse effects of dipipanone are common to all opioid agents, and may include:- respiratory depression; mental clouding, drowsiness and sedation, confusion, mood changes, euphoria, dysphoria, psychosis, restlessness, miosis and raised intracranial pressure; constipation, nausea and vomiting; sweating, facial flushing and hypotension; urticaria and rashes; difficulty with micturition; biliary and renal tract spasm; vertigo.

In addition, cyclizine may cause urticaria, drug rash, drowsiness, dryness of the mouth, nose and throat, blurred vision, tachycardia, urinary retention, constipation, restlessness, nervousness, insomnia and auditory and visual hallucinations, particularly when dosage recommendations have been exceeded. Other central nervous system effects which have been reported rarely include dystonia, dyskenesia, extrapyramidal motor disturbances, tremor, twitching, muscle spasms, convulsions, disorientation, dizziness, decreased consciousness and transient speech disorders. Cholestatic jaundice has occurred in association with cyclizine. Single case reports have been documented of fixed drug eruption; generalised chorea; hypersensitivity hepatitis and agranulocytosis.

Go to top of the page
4.9 Overdose

The signs of overdosage with Diconal are typically those of opioid poisoning i.e. respiratory depression, pin-point pupils, hypotension, circulatory failure and deepening coma. Mydriasis may replace miosis as asphyxia intervenes. Drowsiness, floppiness, miosis and apnoea have been reported in children, as have convulsions.

General supportive measures should be employed as required. Gastric lavage should be performed if indicated. The specific opioid antagonist naloxone is the treatment of choice for the reversal of coma and the restoration of spontaneous respiration; the literature should be consulted for details of appropriate dosage. Patients should be monitored closely for at least 48 hours after recovery in case of relapse, since the duration of action of the antagonist may be substantially shorter than that of dipipanone.

Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

The onset of analgesic action of dipipanone is approximately one hour and lasts for 4 to 6 hours. Cyclizine produces its anti-emetic effect within 2 hours and lasts for approximately 4 hours.

Go to top of the page
5.2 Pharmacokinetic properties

Dipipanone is absorbed from the gastrointestinal tract. It is metabolised in the liver and excreted in the urine and faeces, although data on the proportions of parent compound and metabolites so excreted are lacking.

In healthy adult volunteers, the administration of a single oral dose of 50 mg cyclizine resulted in a peak plasma concentration of approximately 70 nanogram/ml occurring approximately 2 hours after drug administration. The plasma elimination half-life was approximately 20 hours.

The N-demethylated derivative, norcyclizine, has been identified as a metabolite of cyclizine. Norcyclizine has little antihistaminic (H1) activity compared with cyclizine and has a plasma elimination half life of approximately 20 hours. After a single oral dose of 50 mg cyclizine given to a single adult male volunteer, urine collected over the following 24 hours contained less than 1% of the total dose administered.

Go to top of the page
5.3 Preclinical safety data

No additional data of relevance.

Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Lactose, starches, dye (FD and C Red No. 3), gelatin, magnesium stearate.

Go to top of the page
6.2 Incompatibilities

None stated.

Go to top of the page
6.3 Shelf life

60 months.

Go to top of the page
6.4 Special precautions for storage

Store below 25°C. Protect from light. Keep dry.

Go to top of the page
6.5 Nature and contents of container

PVC/aluminium foil blister packs containing 50 tablets.

Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.

Go to top of the page
7. Marketing authorisation holder

Amdipharm PLC

Trading as Amdipharm

Regency House

Miles Gray Road



SS14 3AF

Go to top of the page
8. Marketing authorisation number(s)

PL 20072/0009

Go to top of the page
9. Date of first authorisation/renewal of the authorisation

15th September 2003

Go to top of the page
10. Date of revision of the text


More information about this product

Link to this document from your website:

Active Ingredients/Generics